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ABSTRACT
So far, among the different non-invasive
neurostimulation methods, only
transcutaneous supraorbital nerve stimulation
(t-SNS) with the Cefaly (Cefaly Technology
sprl, Herstal, Belgium) device has randomized
controlled trial-based evidence for safety and
efficacy and obtained American Food and Drug
Administration approval for the prevention of
episodic migraine. In a double-blinded,
randomized, sham-controlled trial on 67
episodic migraine patients (mean
pre-treatment migraine days/month: 6.9), the
50% responder rate after 3 months was
significantly higher in the active group
(38.2%) than in the sham group (12.1%);
attack frequency and total headache days were
also significantly reduced, but not headache
severity. Acute anti-migraine drug intake was
reduced by 36.7% in the active group. Statistical
sub-analysis suggested that t-SNS was more
effective in patients with a higher attack
frequency. In a large survey on 2313 Cefaly
users about safety and satisfaction only 4.3% of
subjects reported side effects, all of which were
minor and fully reversible, the most frequent
being intolerance to the paresthesia feeling and
the most severe an allergic skin reaction to the
electrode gel. The efficacy/safety ratio of the
Cefaly device was therefore most favorable,
especially when compared to preventive
anti-migraine drugs. The therapeutic efficacy
of t-SNS with Cefaly with low-frequency
migraine (B5 attacks/month) was recently
confirmed in an open randomized trial. No
published data are available in chronic
migraine. According to preliminary results of a
fluorodeoxyglucose-positron emission
tomography study, Cefaly might exert its
effect in migraine by increasing activity in
Electronic supplementary material The online
version of this article (doi:10.1007/s40122-015-0039-5)
contains supplementary material, which is available to
authorized users.
F. Riederer (&)
Neurological Center Rosenhuegel and Karl
Landsteiner Institute for Clinical Epilepsy Research
and Cognitive Neurology, Vienna, Austria
e-mail: franz.riederer@uzh.ch
S. Penning
R&D Department, Cefaly Technology, Liege,
Belgium
J. Schoenen
Headache Research Unit, Department of Neurology
and GIGA-Neurosciences, Lie`ge University, Liege,
Belgium
Pain Ther (2015) 4:135–147
DOI 10.1007/s40122-015-0039-5
crucial areas of the limbic system and salience
matrix such as orbitofrontal and anterior
cingulate cortices.
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INTRODUCTION
Migraine is the most prevalent neurological
disorder and is characterized by recurrent
headache attacks associated with
gastrointestinal symptoms and sensoriphobia
[1–3]. Due to the disabling headache and
associated symptoms, migraine significantly
impairs quality of life [4, 5] and is the sixth
most disabling disease worldwide according to
the Global Burden of Disease Study 2013 [6]. At
present, there is no definitive cure for migraine,
but various treatments are available to manage
the disease. Migraine management includes
acute and preventive treatments: acute
treatments aim at interrupting an attack and
restore normal function [7, 8], while preventive
treatments have the disease-modifying
objective of reducing attack frequency and
severity [8–11]. Currently, migraine is mostly
managed using pharmacologic treatments [10].
The most commonly used drugs to stop
migraine attacks are analgesics, non-steroidal
anti-inflammatory drugs (NSAIDs), and triptans
[8, 10–13]. Effective preventive drugs include
beta-blockers (e.g., metoprolol, propranolol,
bisoprolol, candesartan), calcium channel
blockers (such as flunarizine or verapamil),
and the anticonvulsants topiramate and
valproate [8–10, 12–14], while nutraceuticals
like riboflavin, co-enzyme Q10, magnesium or
feverfew have lower efficacy [15].
Most of preventive anti-migraine drugs have
contraindications and are associated with
moderate to severe side effects [9, 12, 13,
16–19]. Importantly, these side effects,
combined with insufficient efficacy, frequently
lead to dissatisfaction and discontinuation [17,
18, 20]. In a large United States health insurance
survey, 73.4%, 70.2%, and 67.6% of patients
who initiated migraine prophylaxis with
antidepressants, anticonvulsants, and
beta-blockers, respectively, were designated
non-adherent after 6 months [21].
In patients with frequent and/or prolonged
migraine attacks, excessive consumption of
acute anti-migraine drugs may lead to
headache chronification, i.e., medication
overuse headache [13, 18], which worsens the
patients’ condition [8, 10, 22].
Moreover, some patients, in particular those
suffering from chronic migraine, become
resistant to conventional medications used to
treat and prevent migraine and thus do not
achieve sufficient pain relief [22–27].
To sum up, 80% of patients are willing to
change their current medication for a treatment
with similar efficacy but fewer side effects [20].
Medication-related adverse effects and lack of
efficiency thus underscore the need for better
anti-migraine treatments and have created a
niche for non-pharmacologic therapies such as
neurostimulation.
Peripheral nerve stimulation (PNS)
represents an emerging, neurostimulation
alternative to treat and prevent migraine [22,
24, 27]. Percutaneous sub-occipital nerve
stimulation (ONS) was first considered as a
treatment for chronic headaches in 1999 [22,
28, 29]. Many non-controlled studies reported
reduction in headache frequency, severity and
headache-related disability after ONS in chronic
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migraine, but the global effect in three
sham-controlled trials was not overwhelming
[25, 30–35]. The combination of percutaneous
ONS and supraorbital nerve stimulation (SNS)
was claimed to have a better effect, but a
randomized controlled trial is lacking [22, 36,
37]. Stimulation of the vagus nerve (VNS) with
implantable electrodes in the neck was found
effective for migraine prevention in a few case
reports and stimulation of the sphenopalatine
ganglion with a microstimulator implanted in
the pterygopalatine fossa is being studied for
migraine treatment [19, 22, 24, 38]. The common
denominator of these neurostimulation
methods is that they are invasive and applicable
only to themost disabled patients with frequent,
severe and drug refractory migraine [16, 27]. For
instance,ONS that requires implantationof leads
in the neck and of a battery in a subcutaneous
pocket is associated with major adverse events
(AE), chiefly electrode migration, battery
depletion and replacement or infections,
leading to multiple surgical interventions [19,
22, 25, 26, 28].
The development of non-invasive
transcutaneous stimulators opened the field of
neurostimulation therapy to all migraine
patients without consideration of disability or
drugrefractoriness [19, 23].Thesemethodscanbe
subdivided into transcranial neurostimulations,
chiefly magnetic or direct current, and
transcutaneous stimulations of pericranial
nerves. Transcranial direct current stimulation
(tDCS) showed encouraging results in migraine
prevention [19, 22]. Transcranial magnetic
stimulation (TMS) was approved by the
American Food and Drug Administration (FDA)
for acute treatment of migraine with aura attacks
[39]. Promising results were also associated with
TMS and repetitive TMS (rTMS) for preventive
treatment of migraine, although large
sham-controlled trials are lacking [19, 22].
Regarding VNS, a transcutaneous device applied
in theneckwas found effective for acutemigraine
treatment in two open studies [40, 41].
Concerning SNS, the transcutaneous Cefaly
device (Cefaly Technology sprl, Herstal,
Belgium) showed a significant reduction in both
migraine attacks and headache days in a
randomized sham-controlled trial [16].
Consequently, in March 2014, Cefaly was the
first medical device approved by the FDA for the
prevention of migraine.
In this paper, we will review in detail the
available data for Cefaly device as a migraine
treatment including technical aspects, effect size,
and safety, as well as possible explanations for its
mode of action. These data will provide better
insight into the therapeutic potentials of the
device as a non-pharmaceutical, non-invasive
migraine treatment, and allow determination of
how this product fits into the available
armamentarium for the management of
migraine patients. This article is based on
previously conducted studies and does not
involve any new studies of human or animal
subjects performed by any of the authors.
TECHNICAL ASPECTS
Cefaly is an external neurostimulator designed
for transcutaneous SNS (t-SNS), also known as
external trigeminal nerve stimulation (e-TNS)
[42]. It is a constant current generator for a
maximum skin impedance of 2.2 kOhms. In
practice, the electrical impulses generated by
the Cefaly headband are transmitted
transcutaneously via a self-adhesive,
supraorbital electrode to excite (trigger action
potentials) on the supratrochlear and
supraorbital branches of the ophthalmic nerve
(V1) located under the skin of the forehead
(Fig. 1). Parameters of the generated electrical
impulses are as follows: rectangular biphasic
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compensated impulses with an electrical mean
equal to zero, impulse width of 250 lS,
frequency of 60 Hz, maximum intensity of
16 mA with a progressive slope from 1 to
16 mA over 14 min.
The patient has to use the device in daily
sessions of 20 min preferably in the evening.
The multiuse electrode has a central pin that
interlocks with the median part of the device to
get the metallic contact blades in connection
with the conductive areas of the electrode.
Cefaly operates on direct electrical energy
provided by two 1.5 V AAA batteries. As the
current intensity progressively increases, the
patient has the possibility to stabilize the
intensity when the tingling or prickling
forehead sensation becomes uncomfortable.
The Cefaly device has an in-built software
that allows monitoring of the number of
completed sessions, and thus compliance.
CLINICAL TRIALS
Pilot Trials
Between 2007 and 2008, a pilot trial performed
in 10 patients to assess safety and efficacy of
Cefaly showed a decrease of the average
migraine attack frequency from 3.9 to 2.8 per
month and 5 out of 8 patients were satisfied
with the device [43]. In the same pilot trial,
when Cefaly was used as an acute treatment
(total of 30 attacks), total relief without rescue
medication was obtained in 13% of attacks,
postpone drug intake in 20% of attacks and
partial relief with additional drug treatment in
45% of attacks. In 2008, an unpublished safety
and acceptance trial was conducted by
Laboratoire Spincontrol (Tours, France) on 32
subjects using Cefaly. The device was
considered ‘‘simple to use’’ by 94% of subjects.
No adverse effects related to Cefaly were
reported during these pilot trials.
The PREMICE Trial
An investigator-driven randomized controlled
trial with Cefaly in migraine prevention was
conducted between 2009 and 2011 under the
auspices of the Belgian Headache Society. This
PREvention of MIgraine using Cefaly (the
PREMICE) study was a prospective,
multicenter, double-blinded, randomized and
sham-controlled trial conducted in five Belgian
headache clinics. The study included 67
patients with at least 2 migraine attacks per
month. After a 1-month baseline period,
patients were randomized to verum or sham
stimulation for a 3-month treatment period
[16].
The intention-to-treat analysis showed a
significant reduction in migraine days
(P = 0.023) and in headache days (P = 0.011)
between baseline and the third month of
treatment in the verum group, but not in the
sham group (Fig. 2). On average, patients in the
verum group had a reduction of 29.7% in
migraine days and 32.3% in headaches days,
while respective reductions in the sham group
Fig. 1 The electrical impulses generated by the Cefaly
device are transmitted via an electrode to excite the upper
branches of the ophthalmic nerve (V1). These pictures are
the property of Cefaly Technology
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were 4.9% and 3.4%; the differences between
the two groups were significant for headache
days but slightly missed the level of significance
for migraine days. The percentage of patients
having at least 50% reduction in monthly
migraine days between baseline and third
month of treatment (i.e., the 50% responder
rate) was significantly greater in the verum
group than in the sham group (38.2% versus
12.1%, respectively, P = 0.023). The number of
Fig. 2 Results of the PREMICE study. Results are pre-
sented as means or means ± standard deviations where
appropriate. Baseline and treatment period were compared
using the Wilcoxon signed rank test for paired samples.
Comparison of relative changes between verum and sham
groups was assessed using the Wilcoxon rank sum test (also
known as Mann–Whitney U test). P values\0.05 are
considered as signiﬁcant
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migraine attacks was also significantly reduced
in the verum group while attack severity was
reduced but not significantly so. Using Cefaly
induced a significant 36.7% reduction in acute
anti-migraine drug intake (P = 0.006) compared
to the sham group where there was on average a
slight 0.4% increase of drug intake. Overall, the
PREMICE study provided evidence that Cefaly is
a safe and effective preventive treatment for
migraine that reduces considerably disease
burden and acute anti-migraine drug intake
[16].
Additional statistical analyses showed that
age and disease duration did not impact on
outcome, but that the effect size was directly
related to the number of migraine days during
the baseline period [44]. When taking into
account this correlation, the difference in
migraine day reduction between verum and
sham groups reached the level of statistical
significance (P = 0.044, instead of 0.054). This
result suggests that Cefaly might be more
beneficial for patients with more frequent
migraines. In the PREMICE trial, patients had
on average four attacks or seven migraine days
per month during baseline, which is in line with
most trials in episodic migraine [16]. However,
in clinical practice patients with very frequent
or chronic migraine are the most disabled and
might thus benefit from t-SNS Cefaly. Trials
targeting this population of migraineurs are
underway (ClinicalTrials.gov identifier,
NCT02342743).
The percentage of satisfied patients was
significantly higher in the verum group
(70.59%; P = 0.009) than in the sham group
(51.52%) [16]. Compliance was acceptable for
the two groups of patients. The verum group
had a slightly better compliance than the sham
group (55.54 sessions vs. 49.00 sessions per
patient, on average) but this difference was not
significant, which suggests that blinding was
preserved. Partial unblinding was considered
unlikely, since the sham response within the
first months was within the expected range,
based on previous studies. As mentioned in the
original article [16], ‘‘To decrease the risk of
unblinding due to the difference in sensory
perception between verum and sham
stimulators, the investigators and their staff
members committed themselves to the
following: not interrogate patients about
sensory perceptions, not enroll patients
acquainted with each other and avoid physical
contact between patients during visits.’’
There were no adverse effects in either group,
indicating that the Cefaly device is safe [16].
Post-Marketing Survey of 2313 Users
A survey was conducted to confirm the safety of
Cefaly and assess the users’ satisfaction in a
large cohort of headache sufferers who rented
the Cefaly device via the Internet and used the
device for a testing period of 58.2 days on
average. The study was performed between
September 2009 and June 2012 and included
2313 subjects who were assumed to suffer from
migraine on the basis that they were using
triptans for acute treatment [17].
During the test period, 99 patients (4.3%)
reported a total of 104 AEs. The most frequent
AE was intolerance to the local paresthesia
induced by the electrical stimulation (n = 31,
1.3% of users), despite the possibility to
interrupt the gradual current intensity increase
as soon as the forehead sensation becomes
uncomfortable. All patients reporting
paresthesia intolerance stopped using Cefaly
and only four patient users presented persistent
paresthesia for several hours after the end of the
stimulation. The second most frequent AE
(n = 19, 0.8% of users) was arousal and sleep
change: 15 users reported sleepiness or a feeling
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of fatigue during the stimulation while 4
subjects reported insomnia. These findings
were consistent with the sedative effect of the
Cefaly device described in the later mentioned
study with high frequency stimulation. Some
users (n = 12, 0.5%) reported tension-type
headache after using Cefaly. Five users
reported reversible skin irritation due to the
electrode and two subjects presented an allergic
skin reaction at the electrode site. This allergy
was attributed to the acrylate component of the
electrode gel. Consequently, new electrodes
with hypoallergenic high quality gel without
acrylate were developed and are currently
available on the market to replace the previous
model in allergic subjects. All the
aforementioned AEs were minor and
completely reversible supporting that Cefaly is
safe and has excellent tolerability [17].
At the end of the trial period, users were
offered to return the device or to purchase it.
1077 subjects (46.6%) returned the device and
were thus considered to be dissatisfied. Table 1
illustrates compliance indexed by the time of
use determined thanks to the in-built software
for the returned devices. The analysis revealed
that 48 subjects did not even switch on the
device and 157 subjects did not use the Cefaly
device for more than 60 min (3 session of
20 min), while they were assumed to use it
once a day (20 min/day) during 40 days. Using
the Cefaly device for more than 400 min would
probably have been required to achieve a
therapeutic effect over the rental period. Less
than half of subjects who returned the device
(n = 431, 40.0%) used it for more than 400 min;
the true (‘‘per protocol’’) non-responder rate
could thus be 18.6%. Among the 646 subjects
who used the device for less than 400 min, 56
(8.7%) reported AEs, twice more than in the
total group of 2313 subjects (4.28%). This rather
high prevalence of AEs that probably reduced
compliance and the lack of a therapeutic effect
partly because of insufficient use may explain
why 46.6% of subjects returned the device [17].
The remaining 1236 users (53.4%) purchased
the Cefaly device after the rental period, which
could be taken as an indicator of their
satisfaction [17]. This satisfaction rate is lower
than the 70.6% observed in the PREMICE study
[16]. The difference may have two main
reasons. First, the satisfaction rate was
influenced by the willingness to pay in the
current survey. The decision to return the
device may also be influenced by the financial
aspect in addition to lack of efficacy or
satisfaction. Second, the subjects had to decide
to keep the device after an average period of
58 days, while the PREMICE study shows that
the maximal reduction in migraine frequency
only occurs after 3 months of treatment with





(% out of the 1077 patients)
0 48 (4.46%)
1 to 20 58 (5.39%)
21 to 40 46 (4.27%)
41 to 60 53 (4.92%)
61 to 100 78 (7.24%)
101 to 200 174 (16.16%)
201 to 400 189 (17.55%)
[400 431 (40.02%)
Reproduced from [17]: Magis D, Sava S, d’Elia TS, Baschi
R, Schoenen. Safety and patients’ satisfaction of
transcutaneous supraorbital neurostimulation (tSNS)
with the Cefaly device in headache treatment: a survey
of 2313 headache sufferers in the general population.
J Headache Pain. 2013;14:95. This is an open access article
distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/
by/2.0)
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the Cefaly device. Therefore, the rental period
may have been too short for some users to
achieve a sufficient level of efficacy.
The survey confirmed that the Cefaly device
is a safe, well-tolerated treatment for migraine
headaches and that 53.4% of subjects purchased
the device at the end of the testing period. Only
4.3% of users reported AEs that were all minor
and completely reversible [17].
Very recently an open trial was conducted on
24 episodic migraine without aura, having B5
attacks per month with an average of 4.5 ± 0.24
migraine days per month, and having never
been treated with migraine preventive
medication. t-SNS with the Cefaly device was
applied for 2 months with a daily session of
20 min. Per protocol analysis was performed on
the 20 compliant patients, i.e., those who used
the device for at least two-thirds of the
recommend total time (i.e., C800 min of t-SNS
neurostimulation). Between run-in and the
second month, the 50% responder rate for
migraine days was 75% (P\0.001) and 81%
for migraine attacks (P\0.001); intake of acute
migraine drugs was as well significantly reduced
[45].
Studies on Possible Modes of Action
The precise mode of action of pericranial nerve
neurostimulation methods in migraine is not
determined. The initial rationale for their use
postulated that convergence of somatic afferents
from the trigeminal or the C2 territories with
visceral trigeminovascular afferents on spinal
trigeminal nucleus nociceptors may block
ascending impulses in the pain pathway. This
hypothesis was not confirmed in studies
exploring the effect of per- or transcutaneous
ONS on trigeminal nociceptor sensitivity [18]. In
a fluorodeoxyglucose-positron emission
tomography (FDG-PET) study of refractory
cluster headache patients before and after
long-term percutaneous ONS treatment [46],
the only significant difference in responders was
an increase in metabolism in the perigenual
anterior cingulate gyrus, which suggests that
ONS may act by changing activity in top-down
pain control. Fewphysiological studieshave been
performed with the Cefaly device. The three
studies described below do not solve the
question about its mechanisms of action, but
they may stimulate the discussion and further
research.
Trial on Sedative Effects
A sedative effect was demonstrated by a
double-blinded, crossover, sham-controlled
study on 30 healthy volunteers who
underwent a series of 4 stimulation protocols
in random order: no stimulation (blank control,
BC), sham stimulation (sham control, SC), low
frequency (2.5 Hz) neurostimulation (LFN), and
high frequency (120 Hz) neurostimulation
(HFN). t-SNS sessions using the Cefaly device
lasted 20 min. The sedative effect related to
each of the four different conditions was
assessed using the Psychomotor Vigilance Task
(PVT), the Critical Flicker Fusion Frequency
(CFFF), the d2 test, and the Fatigue Visual
Numeric Scale (FVNS). These tests are
described in detail in [47].
The results showed that the HFN with the
Cefaly device induced a significant increase in
PVT reaction time and FVNS score (P\0.001),
as well as a significant decrease in CFFF
(P\0.001), all indicating a mild decrease in
vigilance during stimulation. The three other
conditions (BC, SC, and LFN) were not
associated with sedative effects. On the whole,
this study showed that HFN with the Cefaly
device induces a sedative effect in healthy
volunteers.
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Study of Pericranial Electromyography
Activity
Recently, a study evaluated in 23 chronic
migraine patients the effect of t-SNS with the
Cefaly device on pericranial and neck muscle
activity using quantitative electromyography
(EMG) recordings [48]. Activity in frontalis,
anterior temporalis, auricularis posterior, and
middle trapezius muscles was recorded with
surface EMG before and during stimulation
with the Cefaly device. The results showed
that the neurostimulation induced an increase
of median frequency and amplitude of the
myoelectrical signal in all muscles recorded
except in frontalis muscles. The significance of
this finding for the mode of action of the Cefaly
device is doubtful, the more so that is unlikely
that pericranial muscle activity plays a role in
chronic migraine [49].
Cerebral FDG Uptake Changes
Preliminary results of an FDG-PET study in
episodic migraine patients before and after
3 months of daily t-SNS with the Cefaly device
were most recently presented at the
International Headache Society Congress (IHC
2015, May 14–17, Valencia, Spain) [50].
Fourteen migraine patients recorded before
and after neurostimulation were compared to
14 healthy untreated volunteers. Compared to
the latter, at baseline patients were
hypometabolic in the fronto-temporal regions
(P\0.001), especially in the orbitofrontal and
perigenual anterior cingulate cortex. There was
no significant effect on brain metabolism after
one session with the Cefaly device. In
compliant patients (n = 10), daily t-SNS with
the Cefaly device for 3 months was followed by
a normalization of the orbitofrontal
hypometabolism [MNI (Montreal Neurological
Institute) coordinates: -10, 32, -22, familywise
error-corrected P value\0.01]. In previous
studies, the orbitofrontal cortex was found
hypometabolic [51] or hypotrophic [52] in
medication overuse headache, particularly so
in patients not responding to treatment [53].
Like ONS in cluster headache, t-SNS with the
Cefaly device might thus exert its beneficial
effect in migraine via slow neuromodulatory
mechanisms involving limbic and pain control
areas in the cerebral cortex.
DISCUSSION
Migraine is one of the most frequent disabling
diseases. Developing a safe, effective migraine
treatment is thus a high-priority issue. In this
context, the Cefaly device may represent a
first-line non-pharmacologic preventive
migraine treatment. The potential benefits,
advantages, and limitations of neurostimulation
with the Cefaly device are identified and
discussed.
t-SNS using the Cefaly device was shown to
be efficient by decreasing migraine and
headache days significantly more than sham
stimulation. The device also reduced the
number of migraine attacks. Patients using the
Cefaly device reported no severe side effects and
all the infrequent AEs collected were minor and
completely reversible. Consequently, the Cefaly
device allows to efficiently and safely prevent
and treat episodic migraine.
For the discussion, the therapeutic results
obtained with the Cefaly device can be
compared to the pooled results obtained in
placebo-controlled trials with one of the most
potent anti-migraine preventive drugs,
topiramate. The 50% responder rate is 38.2%
for the Cefaly device, 45.3% for topiramate [54].
The responder rate for the sham Cefaly device is
12.1%, 21.8% for the topiramate placebo [54].
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Therefore, the therapeutic gain is 26.1% for the
Cefaly device but 23.5% for the topiramate.
Topiramate is more effective than the Cefaly
device in reducing migraine days and attacks.
However, in the trials with topiramate half of
patients had drug-related side effects and 25%
of patients abandoned the drug because of
intolerable adverse effects [54]. According to
these results, the Cefaly device has a superior
efficacy/safety ratio, which indicates that it
merits to be proposed for episodic migraine
prevention prior to prescribing topiramate. As
for other non-invasive neurostimulation
methods, compliance could be a problem with
the Cefaly device, although it can be optimized
by sustained patient education.
As the Cefaly device is a non-pharmacologic
treatment, it represents analternative forpatients
resistant to common anti-migraine drugs or
intolerant to their side effects. It can also be
combined without reluctance with
pharmacological treatments. The device has
very limited contraindications compared to
preventive anti-migraine drugs. Only patients
with recent brain or facial trauma cannot use the
device. Some patients may be
electro-hypersensitive and not tolerate the
sensation induced by electrical stimulation, but
they representaminorityof theheadache sufferer
population. For patients allergic to acrylate,
hypoallergenic electrodes are now available.
Overall, the Cefaly device could be proposed to
patients who prefer non-pharmacologic
treatments, or who have contraindications to
the usual preventive anti-migraine drugs or do
not tolerate them. Last but not least, the Cefaly
device allows to significantly reduce acute
anti-migraine medication use and therefore
reduces the risk for chronification of migraine
by acute medication overuse, which represents a
pharmaco-economical advantage.
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